Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Personalized drug strategy aims to control Tough-to-Treat blood cancer

NCT ID NCT05478512

Summary

This study is testing a personalized treatment plan for young adults with a high-risk form of chronic lymphocytic leukemia (CLL), a type of blood cancer. All participants start with a two-drug combination. Their treatment path is then customized based on how much cancer remains in their body. Some participants may stop treatment early, while others continue with different drug combinations to try to control the disease long-term.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Ematologia AO di Perugia

    Perugia, Italy

  • Ematologia AOU Careggi

    Florence, Italy

  • Ematologia AOUS - Policlinico S. M. alle Scotte

    Siena, Italy

  • Ematologia IRST D.Amadori

    Meldola, Italy

  • Ematologia Ospedale Infermi

    Rimini, Italy

  • Ematologia Ospedale S.M. delle Croci

    Ravenna, Italy

  • Ematologia Policlinico Gemelli

    Roma, Italy

  • Ematologia Policlinico Umberto I

    Roma, Italy

Conditions

Explore the condition pages connected to this study.